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$10,899 per QALY gained (in 2006). These results were robust
to sensitivity analyses. CONCLUSION: Entecavir was projected
to be clinically and economically attractive in treating lamivu-
dine refractory CHB patients. Further economic modeling upon
the availability of head-to-head clinical trials will be helpful to
conﬁrm these ﬁndings.
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OBJECTIVES: The aim of this study was to collect comparable
and reliable data on the antibiotic therapy in Slovakia during the
period 1996–2005. The special interest was paid to the trend of
antibiotic usages. METHODS: Data of wholesalers (following
ATC/DDD), who are legally obliged provide this information to
the Slovak Institute for Drug Control, was used for the analysis.
The results were expressed in ﬁnance units (€) and deﬁned daily
doses per 1000 inhabitants per day (DID). RESULTS: The col-
lected data showed slight decrease in antibiotic consumption
from 1996 to 2005 in term of DID—in 1996 (26.42), in 2000
(25.05) and in 2005 (25.11). We can see a noticeable increase 
in consumption of macrolides (DID)—in 1996 (3.08), in 2000
(2.99) and in 2005 (4.44) and signiﬁcant increase in ﬂuoro-
quinolones consumption—in 1996 (0.73), in 2000 (1.55) and 
in 2005 (2.01). A signiﬁcant decrease in ﬁrst-generation
cephalosporins consumption—in 1996 (1.17), in 2000 (1.13)
and in 2005 (0.45), and a noticeable increase in consumption of
second-generation cephalosporins—in 1996 (0.79), in 2000
(1.24) and in 2005 (2.27) can be seen from this analysis. The
results show that consumption of combinations of penicillins
incl. beta-lactamase has increased—in 1996 (2.24), in 2000
(3.72) and in 2005 (4.83), but consumption of beta-lactamase
sensitive penicillins has decreased—in 1996 (4.79), in 2000
(4.11) and in 2005 (2.81) in term of DID. From this study, the
stable antibiotics consumption in ﬁnancial term—in 1996
(39,171,000 €), in 2000 (42,556,000 €) and in 2005 (39,985,000
€) can be seen. CONCLUSION: Inseparable components of the
Slovak drug policy must be viewed realistically with regard to
the antibiotic consumption. Adherence to principles of antibiotic
policy lead to fundamental short and long term ﬁnancial savings
within health care systems.
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OBJECTIVES: HIV/AIDS incidence and mortality rates have
decreased in the U.S. since 1996 due to the use of effective anti-
retroviral medications and prevention campaigns. The objective
of this study is to analyze the trends of prices, utilization, and
market shares of antiretroviral medications in the U.S. Medicaid
program. METHODS: Antiretroviral drugs include protease
inhibitors (PIs), nucleoside analogs (NRTIs), non-nucleoside
reverse transcriptase inhibitors (NNRTIs), and fusion inhibitors
(FIs). Reimbursement and utilization data from 1991 to 2005
are provided by the Centers for Medicare & Medicaid Services.
Descriptive time-series analysis was used to assess quarterly pre-
scription numbers, amount of reimbursement, and spending per
prescription. RESULTS: The total reimbursement for antiretro-
viral drugs in the U.S. Medicaid program increased from $ 30.58
million in 1991 to $1.37 billion in 2005. In 2005, NRTIs as a
class had the highest reimbursement market share. These drugs
alone accounted for $608.6 million in Medicaid reimbursements
(44.4% of spending on antiretrovirals). The PIs came in second
at $560.4 million (40.9 percent), and the NNRTIs were third 
at $161.4 million (11.8%). The total number of prescriptions
increased dramatically from 168,914 in 1991 to 1.99 million in
1998, and 2.73 million in 2005. The number of prescriptions 
for NRTIs reached 1.38 million in 2005. Prescriptions for PIs
increased from 114 in 1995 to 928,949 in 2005. The diffusion
of prescriptions for NNRTIs was also rapid from 1,339 pre-
scriptions in 1996 to 401,272 in 2005. Reimbursement per pre-
scription for all drugs, with exception of Agenerase, increased
over time. The relatively expensive drugs in 2005 included
Trizivir ($1040) and Combivir ($640), as well as Reyataz ($750),
Lexiva ($700),Sustiva ($420), Viramune ($370), and Fuzeon
($1914). CONCLUSION: The tremendous growth in antiretro-
viral spending is due in part to growing utilization of newly
developed antiretroviral drugs and in part to rising prices of
existing medications.
PIN30
SMOKING STATUS AND PNEUMONIA IMMUNIZATION:
FINDINGS FROM THE 2005 BEHAVIORAL RISK FACTOR
SURVEILLANCE SYSTEM (BRFSS) DATA
Parekh RH, Kamal KM, Desselle SP
Duquesne University, Pittsburgh, PA, USA
OBJECTIVES: Cigarette smoking population is at high risk of
pneumococcal diseases. The study objectives are: 1) estimating
pneumococcal immunization rate in cigarette smoking popula-
tion (50 years and above), and 2) assessing the differences in
sociodemographic and health-related characteristics of those
immunized and non-immunized for pneumonia within this popu-
lation. METHODS: The study used 2005 Behavioral Risk 
Factor Surveillance System (BRFSS) survey. The smoking popu-
lation was extracted based on the question “Have you smoked
at least 100 cigarettes in your entire life?” Within this popula-
tion pneumonia vaccination status was assessed based on the
response to the question “Have you ever had a pneumonia
shot?” Descriptive, univariate, and multivariate statistics were
used to compare those immunized with those not immunized on
the basis of sociodemographic and health-related characteristics.
Data extraction and analysis were performed on weighted data
using SPSS 13.0. RESULTS: Of the total cigarette smoking popu-
lation (n = 97,342; 50 years and above), only 44.2% (n =
41,005) were immunized for pneumonia. Pneumonia immuniza-
tion rate was 31.4% in 50–64 years age group and 68.6% in 65
and above age group. Whites who smoked had a higher immu-
nization rate (71.8%) compared with non-whites (28.2%).
Those with health insurance coverage had higher immunization
rate (95.4%) than those who had no health insurance coverage
(4.6%). Immunization rates were lowest for those with educa-
tion less than high school (15.2%), followed by high school
(34.9%) and highest for greater than high school (49.9%).
Results from logistic regression indicated that those with health
care coverage (OR = 1.789) and with comorbid conditions (OR
= 1.427–2.298) were more likely to be immunized with pneu-
mococcal vaccine. CONCLUSION: Overall, the pneumococcal
immunization rate is low among cigarette smoking population.
Health care providers should identify the high-risk groups such
as those who are 50 years and above, non-whites, who lack of
health insurance coverage and should encourage them to receive
pneumococcal immunization.
